Ameriprise’s Opus Genetics IRD Stock Holding History

Ameriprise’s Portfolio IRD Stock Details IRD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-388,491	Closed	-$1.77M	–	4272
2026 Q1	$1.77M	Buy	+388,491	New	+$1.34M	﹤0.01%	3016
2022 Q4	–	Sell	-30,099	Closed	-$60K	–	4063
2022 Q3	$60K	Hold	30,099	–	–	﹤0.01%	3882
2022 Q2	$58K	Buy	30,099 +251	+0.8%	+$571	﹤0.01%	3820
2022 Q1	$97K	Buy	+29,848	New	+$102K	﹤0.01%	3849
2014 Q4	–	Sell	-3	Closed	-$1K	–	4470
2014 Q3	$1K	Hold	3	–	–	﹤0.01%	5594
2014 Q2	$1K	Buy	+3	New	+$1.36K	﹤0.01%	5389

Other funds holding IRD

Caligan Partners New York $2.13B AUM 758.65% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return

BCM

BIOS Capital Management Fort Worth, Texas $41.7M AUM 34.92% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return

NCM

Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

BCM

Boxer Capital Management San Diego, California $1.33B AUM 864.5% 1-Year Est. Return

TECP

Trails Edge Capital Partners Atlanta, Georgia $630M AUM

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Ameriprise's IRD Position: Q2 2026 in Review

Ameriprise sold out of Opus Genetics (IRD) in Q2 2026, closing a stake of 388,491 shares — an estimated $1.77M sold.

Ameriprise first reported a position in IRD in Q2 2014 and held it in 6 quarters. The position peaked at $1.77M in Q1 2026. 103 funds tracked by Wall St. Rank hold IRD as of Q2 2026.

Ameriprise reported no remaining Opus Genetics position as of Q2 2026 after selling out during the quarter.
Ameriprise sold 388,491 Opus Genetics shares in Q2 2026, an estimated $1.77M.
Ameriprise first reported a position in Opus Genetics in Q2 2014 and held it in 6 quarters.
Ameriprise's Opus Genetics position peaked at $1.77M in Q1 2026.
103 funds tracked by Wall St. Rank held Opus Genetics as of Q2 2026.

Based on Ameriprise's 13F filing for Q2 2026, filed 14 Aug 2026.